-
-
Overview
-
Specificity: Detects human CD3/CD19. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Blinatumomab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL methodPlease contact us at for specific academic pricing.
Background
Blinatumomab is a bispecific T-cell engager (BiTE). It enables a patient’s T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells.
-
- Properties
- Applications
-
Overview